98. 好酸球性消化管疾患 Disease details / Clinical trials / Drug dev / DR info

AK002
   Allakos Inc.
      2020   Phase 2;Phase 3   EUCTR2019-004391-19-NL   Australia;Netherlands;United States;
   Allakos, Inc.
      2021   Phase 3   NCT04856891   United States;
      2018   Phase 2   NCT03664960   United States;
      2018   Phase 2   NCT03496571   United States;
APD334
   Arena Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2020-003226-23-NL   Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States;
      2021   Phase 2   EUCTR2020-003226-23-DE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
      2021   Phase 2   EUCTR2020-003226-23-BE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
APT-1011
   Adare Pharmaceutical
      2017   Phase 2   EUCTR2016-004749-10-ES   Belgium;Canada;Germany;Spain;United States;
      2017   Phase 2   EUCTR2016-004749-10-DE   Belgium;Canada;Germany;Spain;Switzerland;United States;
      2017   Phase 2   EUCTR2016-004749-10-BE   Belgium;Canada;Germany;Spain;Switzerland;United States;
   Adare Pharmaceuticals, Inc.
      2017   Phase 2   NCT03191864   Belgium;Canada;Germany;Spain;Switzerland;United States;
   Ellodi Pharmaceuticals, LP
      2021   Phase 3   NCT05083312   Australia;United States;
      2020   Phase 3   NCT04281108   Australia;Germany;Spain;United States;
APT-1011 -
   Adare Pharmaceuticals US, LP
      2020   Phase 3   EUCTR2019-001521-27-ES   Australia;Germany;Spain;Switzerland;United States;
      2020   Phase 3   EUCTR2019-001521-27-DE   Australia;Germany;Spain;United States;
AR401959 L-arginine
   Arena Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2020-003226-23-NL   Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States;
      2021   Phase 2   EUCTR2020-003226-23-DE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
      2021   Phase 2   EUCTR2020-003226-23-BE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
Allergy immunotherapy (allergy shots)
   United States Naval Medical Center, San Diego
      2012   -   NCT01685034   -
BT-11
   Landos Biopharma Inc.
      2022   Phase 1   NCT04835168   -
BUET
   DR. FALK PHARMA GMBH
      2017   Phase 3   EUCTR2014-001485-99-IT   Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Dr. Falk Pharma GmbH
      2017   Phase 3   EUCTR2014-001485-99-DK   Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2014-001485-99-NL   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2014-001485-99-BE   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      2016   -   EUCTR2014-001485-99-ES   Spain;Switzerland;
      2015   Phase 3   EUCTR2014-001485-99-GB   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      2015   Phase 3   EUCTR2014-001485-99-DE   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      2015   Phase 3   EUCTR2014-001484-12-NL   Belgium;Germany;Netherlands;Spain;Switzerland;
      2015   Phase 3   EUCTR2014-001484-12-ES   Belgium;Germany;Netherlands;Spain;Switzerland;
      2015   Phase 3   EUCTR2014-001484-12-DE   Belgium;Germany;Netherlands;Spain;Switzerland;
      2015   Phase 3   EUCTR2014-001484-12-BE   Belgium;Germany;Netherlands;Spain;Switzerland;
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland;
BUL
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland;
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland;
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland;
BUU 0.4mg/ml
   Dr. Falk Pharma GmbH
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland;
Barium
   Mayo Clinic
      2017   -   NCT03290482   United States;
      2013   -   NCT01865825   United States;
Beclomethasone dipropionate
   Penn State University
      2010   Phase 1   NCT01016223   United States;
Benralizumab
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-002871-32-IT   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
   AstraZeneca
      2022   Phase 3   NCT05251909   Australia;Brazil;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United States;Vietnam;
      2020   Phase 3   NCT04543409   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-002871-32-NL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002871-32-GB   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002871-32-FR   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002871-32-ES   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002871-32-DE   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002871-32-PL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
   Hibi Kazushige
      2022   Phase 3   JPRN-jRCT2031210500   America;Australia;Brazil;Canada;China;France;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;Vietnam;
      2020   Phase 3   JPRN-jRCT2061200026   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russia;Spain;UK;US;
Bethanechol
   University of Iowa
      2014   Phase 2   NCT02058537   United States;
Budesonide
   IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
      2019   Phase 2   EUCTR2019-002691-14-IT   Italy;
   Mayo Clinic
      2008   Phase 2/Phase 3   NCT00728481   United States;
   Shire
      2009   Phase 2   NCT00762073   United States;
   Swiss EE Study Group
      2005   Phase 2   NCT00271349   Switzerland;
Budesonide 0.5 mg compresse orodispersibili
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland;
Budesonide 0.5 mg orodispersible tablets
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland;
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland;
Budesonide 0.5mg orodispersible tablet twice daily
   Dr. Falk Pharma GmbH
      2016   Phase 3   NCT02493335   Germany;
Budesonide 1 mg compresse orodispersibili
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland;
Budesonide 1 mg orodispersible tablets
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland;
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland;
Budesonide 1 mg orodispersible tablets (BUL 1 mg)
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2020-001314-37-DE   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
      2021   Phase 3   EUCTR2020-001314-37-AT   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
Budesonide 1mg orodispersible tablet twice daily
   Dr. Falk Pharma GmbH
      2016   Phase 3   NCT02493335   Germany;
      2015   Phase 3   NCT02434029   Germany;
Budesonide 2 mg orodispersible tablets (BUL 2 mg)
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2020-001314-37-PT   Austria;Germany;Portugal;Spain;Switzerland;
      2021   Phase 3   EUCTR2020-001314-37-DE   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
      2021   Phase 3   EUCTR2020-001314-37-AT   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
Budesonide [0.4mg/ml] viscous suspension
   Dr. Falk Pharma GmbH
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland;
Budesonide oral suspension
   Shire
      2017   Phase 3   NCT03245840   United States;
Budesonide oral suspension [0.2 mg/ml]
   Dr. Falk Pharma GmbH
      2020   Phase 2;Phase 3   EUCTR2017-003737-29-NL   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
      2019   Phase 2;Phase 3   EUCTR2017-003737-29-PT   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
      2019   Phase 2;Phase 3   EUCTR2017-003737-29-GR   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
      2019   Phase 2;Phase 3   EUCTR2017-003737-29-GB   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
      2019   Phase 2;Phase 3   EUCTR2017-003737-29-ES   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
      -   Phase 2;Phase 3   EUCTR2017-003737-29-DE   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
Budesonide plus Prevacid
   Ranjan Dohil
      2008   Phase 2   NCT00638456   United States;
CALY-002
   Calypso Biotech BV
      2020   Phase 1   NCT04593251   Belgium;Germany;Netherlands;
CC
   Hatano Ben
      2021   Phase 3   JPRN-jRCT2051200140   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;UK;United States of America;
   Zhang Changliang
      2022   Phase 3   JPRN-jRCT2031210574   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States of America;
      2022   Phase 3   JPRN-jRCT2021210067   Japan;
CC-93538
   CELGENE INTERNATIONAL II SàRL
      2022   Phase 3   EUCTR2020-004335-24-IT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004336-16-IT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
   Celgene
      2021   Phase 3   NCT04991935   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   NCT04753697   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Puerto Rico;Spain;Switzerland;United Kingdom;United States;
   Celgene International II Sàrl
      2022   Phase 3   EUCTR2020-004336-16-ES   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-004335-24-PT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-004335-24-DE   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004336-16-PT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004336-16-PL   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004336-16-DE   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004336-16-BE   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004336-16-AT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004335-24-BE   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004335-24-AT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Cendakimab
   CELGENE INTERNATIONAL II SàRL
      2022   Phase 3   EUCTR2020-004335-24-IT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004336-16-IT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
   Celgene International II Sàrl
      2022   Phase 3   EUCTR2020-004336-16-ES   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-004335-24-PT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-004335-24-DE   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004336-16-PT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004336-16-PL   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004336-16-DE   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004336-16-BE   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004336-16-AT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004335-24-BE   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004335-24-AT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Citalopram
   Amsterdam UMC
      2021   Phase 4   EUCTR2021-002288-24-NL   Netherlands;
Compressa effervescente 0,5 mg di budesonide per uso orodispersibile
   DR. FALK PHARMA GMBH
      2017   Phase 3   EUCTR2014-001485-99-IT   Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Compressa effervescente 1 mg di budesonide per uso orodispersibile
   DR. FALK PHARMA GMBH
      2017   Phase 3   EUCTR2014-001485-99-IT   Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Cortisol
   University of Colorado, Denver
      2022   -   NCT05246085   -
Dexlansoprazole
   Mayo Clinic
      2012   Phase 1/Phase 2   NCT01479231   United States;
Dupilumab
   Children's Hospital of Philadelphia
      2022   Phase 4   NCT05247866   United States;
   Regeneron Pharmaceuticals
      2021   -   NCT04776694   -
      2020   Phase 3   NCT04394351   Canada;United States;
      2018   Phase 3   NCT03633617   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 2   NCT02379052   United States;
Dupilumab (blinded)
   Children's Hospital Medical Center, Cincinnati
      2021   Phase 2   NCT03678545   United States;
Dupilumab (open-label)
   Children's Hospital Medical Center, Cincinnati
      2021   Phase 2   NCT03678545   United States;
Dupixent
   Regeneron Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-000844-25-SE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000844-25-PT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000844-25-NL   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000844-25-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000844-25-GB   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000844-25-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000844-25-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000844-25-DE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000844-25-BE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
E0E food introduction-2nd
   Children's Hospital of Philadelphia
      2022   Phase 4   NCT05247866   United States;
ESO-101
   EsoCap AG
      2021   Phase 2   NCT04849390   Germany;Netherlands;Spain;Switzerland;
      2021   Phase 2   EUCTR2020-000082-16-DE   Germany;Netherlands;Spain;Switzerland;
      2020   Phase 2   EUCTR2020-000082-16-NL   Germany;Netherlands;Spain;Switzerland;
EUR-1100
   Aptalis Pharma
      2011   Phase 1/Phase 2   NCT01386112   United States;
   Forest Laboratories
      2012   -   NCT01498497   United States;
EoE Food introduction-3rd dose
   Children's Hospital of Philadelphia
      2022   Phase 4   NCT05247866   United States;
EoE food introduction-1st
   Children's Hospital of Philadelphia
      2022   Phase 4   NCT05247866   United States;
Esomeprazole
   Mayo Clinic
      2008   Phase 2/Phase 3   NCT00728481   United States;
   University of Utah
      2004   Phase 2   NCT00123656   United States;
   Walter Reed Army Medical Center
      2008   -   NCT00895817   United States;
EsophaCap
   Mayo Clinic
      2017   -   NCT03290482   United States;
Esophageal dilation
   Vanderbilt University
      2008   -   NCT00880906   United States;
Esophagogastroduodenoscopy
   University of Utah
      2016   Early Phase 1   NCT04069429   United States;
Etrasimod
   Arena Pharmaceuticals
      2021   Phase 2   NCT04682639   Australia;Belgium;Netherlands;Spain;Switzerland;United States;
Etrasimod L-arginine
   Arena Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2020-003226-23-NL   Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States;
      2021   Phase 2   EUCTR2020-003226-23-DE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
      2021   Phase 2   EUCTR2020-003226-23-BE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
Famotidine
   Mayo Clinic
      2020   Phase 2   NCT04248712   United States;
Fasenra
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-002871-32-NL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002871-32-DE   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Florence 30 µg/mL
   EMS
      2021   Phase 2   NCT02873468   -
Florence 60 µg/mL
   EMS
      2021   Phase 2   NCT02873468   -
Florence 90 µg/mL
   EMS
      2021   Phase 2   NCT02873468   -
Flovent
   Marc Rothenberg, MD
      2007   Phase 2   NCT00426283   United States;
Fluticasone
   Azienda Policlinico Umberto I
      2012   Phase 4   NCT01846962   Italy;
   Claire Daniels
      2018   Phase 4   NCT03781596   United States;
   Mayo Clinic
      2005   Phase 2   NCT00275561   United States;
   Medical College of Wisconsin
      2012   Phase 3   NCT01702701   United States;
   Technische Universität München
      2011   -   NCT01624129   Germany;
   University of Utah
      2004   Phase 2   NCT00123656   United States;
Fluticasone MDI
   University of North Carolina, Chapel Hill
      2015   Phase 4   NCT02019758   United States;
Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
   Children's Hospital Medical Center, Cincinnati
      2016   Phase 2/Phase 3   NCT02610816   United States;
Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
   Children's Hospital Medical Center, Cincinnati
      2016   Phase 2/Phase 3   NCT02778867   United States;
Fluticasone Propionate, USP
   Adare Pharmaceuticals US, LP
      2020   Phase 3   EUCTR2019-001521-27-ES   Australia;Germany;Spain;Switzerland;United States;
      2020   Phase 3   EUCTR2019-001521-27-DE   Australia;Germany;Spain;United States;
Gold
   Endoscopy Center, Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen University.
      2016   -   ChiCTR-DOD-16009003   China;
High dose budesonide suspension
   Dr. Falk Pharma GmbH
      2011   Phase 2   NCT02280616   Germany;
High dose budesonide tablet
   Dr. Falk Pharma GmbH
      2011   Phase 2   NCT02280616   Germany;
Honey
   Walter Reed National Military Medical Center
      2014   -   NCT02125851   United States;
IRL201104
   Revolo Biotherapeutics
      2021   Phase 2   NCT05084963   United States;
Infliximab
   Swiss EE Study Group
      2007   Phase 2   NCT00523354   Switzerland;
Inhaled/swallowed budesonide
   University of North Carolina, Chapel Hill
      2009   -   NCT00961233   United States;
Intraluminal Impedance
   Mayo Clinic
      2015   Early Phase 1   NCT02353078   United States;
Intubated with Propofol (IP)
   Children's Hospital Medical Center, Cincinnati
      2009   -   NCT02038894   United States;
Intubated with Sevoflurane (IS)
   Children's Hospital Medical Center, Cincinnati
      2009   -   NCT02038894   United States;
Jorveza
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2020-001314-37-DE   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
      2021   Phase 3   EUCTR2020-001314-37-AT   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
Jorveza 0.5 mg compresse orodispersibili
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland;
Jorveza 0.5 mg orodispersible tablets
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland;
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland;
Jorveza 1 mg compresse orodispersibili
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland;
Jorveza 1 mg orodispersible tablets
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2020-001314-37-PT   Austria;Germany;Portugal;Spain;Switzerland;
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland;
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland;
Lirentelimab
   Allakos, Inc.
      2020   Phase 3   NCT04620811   United States;
Lirentelimab (AK002)
   Allakos, Inc.
      2020   Phase 3   NCT04322604   United States;
      2020   Phase 2/Phase 3   NCT04322708   Australia;Netherlands;United States;
Loratadine
   Mayo Clinic
      2020   Phase 2   NCT04248712   United States;
Losartan Potassium
   Children's Hospital Medical Center, Cincinnati
      2017   Phase 2   NCT03029091   United States;
      2013   Phase 2   NCT01808196   United States;
Low dose budesonide tablet
   Dr. Falk Pharma GmbH
      2011   Phase 2   NCT02280616   Germany;
MEDI-563
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-002871-32-IT   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-002871-32-NL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002871-32-GB   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002871-32-FR   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002871-32-ES   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002871-32-DE   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002871-32-PL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Mepolizumab
   Children's Hospital Medical Center, Cincinnati
      2001   Phase 1/Phase 2   NCT00266565   United States;
   GlaxoSmithKline
      2006   Phase 2   NCT00358449   Australia;Canada;United Kingdom;United States;
   GlaxoSmithKline Research & Development Ltd.
      2006   Phase 2   EUCTR2005-006074-10-GB   United Kingdom;
   University of North Carolina, Chapel Hill
      2019   Phase 2   NCT03656380   United States;
Mometasone furoate
   Mogens Bove
      2014   Phase 2   NCT02113267   Sweden;
Montelukast
   Children's Mercy Hospital Kansas City
      2011   -   NCT01458418   United States;
      2005   -   NCT00148603   United States;
   Medical College of Wisconsin
      2012   Phase 3   NCT01702701   United States;
Montelukast/ Singulair
   Mayo Clinic
      2007   Phase 1   NCT00511316   United States;
NIOX MINO® Airway Inflammation Monitor
   Tufts Medical Center
      2010   -   NCT01170234   United States;
Nasonex
   NU-sjukvården, Norra Älvsborgs Länssjukhus
      2013   Phase 2   EUCTR2012-005842-39-SE   Sweden;
Nitric Oxide
   Mayo Clinic
      2013   -   NCT01929824   United States;
Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
   University of North Carolina, Chapel Hill
      2016   -   NCT02722148   United States;
OC000459
   Oxagen Ltd
      2010   Phase 2   NCT01056783   Switzerland;
Omalizumab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2004   Phase 2   NCT00084097   United States;
   O & O Alpan LLC
      2009   Phase 1   NCT01040598   United States;
   University of Utah
      2005   Phase 2   NCT00123630   United States;
Omeprazole
   Claire Daniels
      2018   Phase 4   NCT03781596   United States;
Omeprazole 20 MG Oral Tablet
   Wroclaw Medical University
      2017   -   NCT04803162   Poland;
Omeprazole 20mg BID
   University of Colorado, Denver
      2020   Phase 4   NCT04149470   United States;
Oral Budesonide
   Baylor College of Medicine
      2013   Phase 2   NCT01821898   United States;
Oral Budesonide Suspension (MB-9)
   Shire
      2012   Phase 2   NCT01642212   United States;
Oral Budesonide Suspension (OBS)
   Shire
      2016   Phase 3   NCT02736409   United Kingdom;United States;
      2015   Phase 3   NCT02605837   United States;
Oral Viscous Budesonide
   University of North Carolina, Chapel Hill
      2015   Phase 4   NCT02019758   United States;
Oral Viscous Budesonide (OVB)
   Azienda Policlinico Umberto I
      2012   Phase 4   NCT01846962   Italy;
Oral cromolyn sodium
   University of Tennessee
      2014   Phase 4   NCT02371941   United States;
QAX576
   Novartis Pharmaceuticals
      2009   Phase 2   NCT01022970   United States;
RPC4046
   Celgene
      2014   Phase 2   NCT02098473   Canada;Switzerland;United States;
Reslizumab
   Ception Therapeutics
      2008   Phase 3   NCT00635089   Canada;United States;
      2008   Phase 2/Phase 3   NCT00538434   Canada;United States;
SB-240563
   GlaxoSmithKline Research & Development Ltd.
      2006   Phase 2   EUCTR2005-006074-10-GB   United Kingdom;
SCH55700
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 2   NCT00017862   United States;
Sirolimus
   National Institute of Allergy and Infectious Diseases (NIAID)
      2013   Phase 1   NCT01814059   United States;
Steroid and Proton Pump Inhibitor Therapy
   Vanderbilt University
      2008   -   NCT00880906   United States;
Sucralfate
   Mayo Clinic
      2015   Early Phase 1   NCT02353078   United States;
Swallowed fluticasone
   Walter Reed Army Medical Center
      2008   -   NCT00895817   United States;
Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
   Dallas VA Medical Center
      2007   Phase 4   NCT01404832   United States;
Viaskin Milk 500 mcg
   Children's Hospital of Philadelphia
      2015   Phase 2   NCT02579876   United States;
Viscous/swallowed budesonide
   University of North Carolina, Chapel Hill
      2009   -   NCT00961233   United States;
Vitamin D
   Arkansas Children's Hospital Research Institute
      2019   -   NCT03615950   United States;
Vonoprazan
   Second department of Internal Medicine, Shimane University Faculty of Medicine
      2016   -   JPRN-UMIN000021041   Japan;
Wheat
   Mayo Clinic
      2015   -   NCT02434705   United States;
Xanthan gum
   Walter Reed National Military Medical Center
      2014   -   NCT02125851   United States;
Xylose
   Mayo Clinic
      2014   -   NCT02314455   United States;
Zofran - no intubation
   Children's Hospital Medical Center, Cincinnati
      2009   -   NCT02038894   United States;
budesonide effervescent tablet for orodispersible use
   Dr. Falk Pharma GmbH
      2017   Phase 3   EUCTR2014-001485-99-DK   Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2014-001485-99-NL   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2014-001485-99-BE   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      2016   -   EUCTR2014-001485-99-ES   Spain;Switzerland;
      2015   Phase 3   EUCTR2014-001485-99-GB   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      2015   Phase 3   EUCTR2014-001485-99-DE   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      2015   Phase 3   EUCTR2014-001484-12-NL   Belgium;Germany;Netherlands;Spain;Switzerland;
      2015   Phase 3   EUCTR2014-001484-12-ES   Belgium;Germany;Netherlands;Spain;Switzerland;
      2015   Phase 3   EUCTR2014-001484-12-DE   Belgium;Germany;Netherlands;Spain;Switzerland;
      2015   Phase 3   EUCTR2014-001484-12-BE   Belgium;Germany;Netherlands;Spain;Switzerland;
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland;